Joseph S. Zakrzewski - Mar 24, 2022 Form 3 Insider Report for AN2 Therapeutics, Inc. (ANTX)

Role
Director
Signature
/s/ Lucy Day, Attorney-in-Fact for Joseph Zakrzewski
Stock symbol
ANTX
Transactions as of
Mar 24, 2022
Transactions value $
$0
Form type
3
Date filed
3/24/2022, 09:26 PM
Previous filing
Mar 1, 2022
Next filing
Mar 31, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding ANTX Common Stock 506K Mar 24, 2022 By Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding ANTX Stock Option (right to buy) Mar 24, 2022 Common Stock 100K $6.60 Direct F2
holding ANTX Series A Convertible Preferred Stock Mar 24, 2022 Common Stock 98.2K Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held by Z3 Trust, for which the Reporting Person is a trustee.
F2 The shares subject to the option vest as follows: 1/36th of the shares vests monthly over three years from April 30, 2021, subject to the Reporting Person's continuous service as of such date.
F3 Each share of Preferred Stock automatically converts on a one-for-one basis into Common Stock immediately prior to the closing of the Issuer's initial public offering (the "IPO"), for no additional consideration. The shares of Preferred Stock have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney